Advances in the Colorectal Cancer

Dear Colleagues,

Colorectal cancer is the second leading cause of death from cancer in the United States. In 2023, 1,535,020 new cases of colorectal cancer have been diagnosed with over 52,550 deaths. Although the overall mortality is declining, the mortality has increased from 0.5 to 3% annually in the younger age group (under 55 years of age). There has been an increase in left-sided versus right-sided tumors. The use of immunotherapy regimens for mismatch repair-deficient colorectal cancer and use of targeted therapy, like the combination of trastuzumab and tucatinb for HER2-positive colorectal cancer, has definitely made an impact on outcomes for patients with metastatic colorectal cancer. The use of genomic testing upfront to guide treatment decisions has been key in improving progression-free survival and overall survival for patients with colorectal cancer. In patients with colorectal cancer that have liver-only metastases, the varied liver-directed treatment options, like transarterial chemoembolization, transarterial radioembolization, radiofrequency ablation, liver transplant and use of hepatic artery infusion pump therapy, have accelerated the progress in the metastatic colorectal arena.

In this Special Issue, you are invited as an expert in the field to share your insight and submit a manuscript on the novel research and treatment strategies that have advanced the survival of patients with colorectal cancer.

Dr. Olivia Aranha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• colorectal cancer
• progress
• treatment
• liver-directed therapy
• radiation
• immunotherapy
• mismatch repair deficient
• microsatellite instability
• genomics
• peritoneal carcinomatosis